Literature DB >> 25868935

Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity.

Martin T Strassnig1, Tenko Raykov2, Cedric O'Gorman3, Christopher R Bowie4, Samir Sabbag1, Dante Durand1, Thomas L Patterson5, Amy Pinkham6, David L Penn7, Philip D Harvey8.   

Abstract

Cognition, negative symptoms, and depression are potential predictors of disability in schizophrenia. We present analyses of pooled data from four separate studies (all n>169; total n=821) that assessed differential aspects of disability and their potential determinants. We hypothesized that negative symptoms would predict social outcomes, but not vocational functioning or everyday activities and that cognition and functional capacity would predict vocational functioning and everyday activities but not social outcomes. The samples were rated by clinician informants for their everyday functioning in domains of social and vocational outcomes, and everyday activities, examined with assessments of cognition and functional capacity, rated clinically with the Positive and Negative Syndrome Scale (PANSS) and self-reporting depression. We computed a model that tested the hypotheses described above and compared it to a model that predicted that negative symptoms, depression, cognition, and functional capacity had equivalent influences on all aspects of everyday functioning. The former, specific relationship model fit the data adequately and we subsequently confirmed a similar fit within all four samples. Analyses of the relative goodness of fit suggested that this specific model fit the data better than the more general, equivalent influence predictor model. We suggest that treatments aimed at cognition may not affect social functioning as much as other aspects of disability, a finding consistent with earlier research on the treatment of cognitive deficits in schizophrenia, while negative symptoms predicted social functioning. These relationships are central features of schizophrenia and treatment efforts should be aimed accordingly.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognition; Functional capacity; Negative symptoms; Schizophrenia; Social functioning

Mesh:

Year:  2015        PMID: 25868935      PMCID: PMC4437911          DOI: 10.1016/j.schres.2015.03.033

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  33 in total

1.  Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?

Authors:  Philip D Harvey; Alan S Bellack
Journal:  Schizophr Bull       Date:  2009-01-06       Impact factor: 9.306

2.  Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior.

Authors:  Christopher R Bowie; Susan R McGurk; Brent Mausbach; Thomas L Patterson; Philip D Harvey
Journal:  Am J Psychiatry       Date:  2012-07       Impact factor: 18.112

Review 3.  The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis.

Authors:  Anne-Kathrin J Fett; Wolfgang Viechtbauer; Maria-de-Gracia Dominguez; David L Penn; Jim van Os; Lydia Krabbendam
Journal:  Neurosci Biobehav Rev       Date:  2010-07-08       Impact factor: 8.989

4.  Predictors of the accuracy of self assessment of everyday functioning in people with schizophrenia.

Authors:  Samir Sabbag; Elizabeth W Twamley; Lea Vella; Robert K Heaton; Thomas L Patterson; Philip D Harvey
Journal:  Schizophr Res       Date:  2012-03-02       Impact factor: 4.939

5.  Validating the measurement of real-world functional outcomes: phase I results of the VALERO study.

Authors:  Philip D Harvey; Tenko Raykov; Elizabeth W Twamley; Lea Vella; Robert K Heaton; Thomas L Patterson
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

6.  Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings.

Authors:  Philip D Harvey; Samir Sabbag; Davide Prestia; Dante Durand; Elizabeth W Twamley; Thomas L Patterson
Journal:  J Psychiatr Res       Date:  2012-09-11       Impact factor: 4.791

7.  A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia.

Authors:  Shannon M Couture; Eric L Granholm; Scott C Fish
Journal:  Schizophr Res       Date:  2010-10-20       Impact factor: 4.939

8.  A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes.

Authors:  Til Wykes; Vyv Huddy; Caroline Cellard; Susan R McGurk; Pál Czobor
Journal:  Am J Psychiatry       Date:  2011-03-15       Impact factor: 18.112

9.  Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms.

Authors:  Feea R Leifker; Christopher R Bowie; Philip D Harvey
Journal:  Schizophr Res       Date:  2009-09-22       Impact factor: 4.939

10.  Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden.

Authors:  Philip D Harvey; Lars Helldin; Christopher R Bowie; Robert K Heaton; Anna-Karin Olsson; Fredrik Hjärthag; Torsten Norlander; Thomas L Patterson
Journal:  Am J Psychiatry       Date:  2009-06-01       Impact factor: 18.112

View more
  64 in total

1.  Autism symptoms, depression, and active social avoidance in schizophrenia: Association with self-reports and informant assessments of everyday functioning.

Authors:  Philip D Harvey; Elizabeth Deckler; Mackenzie T Jones; L Fredrik Jarskog; David L Penn; Amy E Pinkham
Journal:  J Psychiatr Res       Date:  2019-05-10       Impact factor: 4.791

2.  Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes.

Authors:  Philip D Harvey; Anzalee Khan; Alexandra Atkins; Richard Se Keefe
Journal:  Psychiatry Res       Date:  2019-01-15       Impact factor: 3.222

3.  Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis.

Authors:  Tyler B Grove; Ivy F Tso; Jinsoo Chun; Savanna A Mueller; Stephan F Taylor; Vicki L Ellingrod; Melvin G McInnis; Patricia J Deldin
Journal:  Psychiatry Res       Date:  2016-06-25       Impact factor: 3.222

4.  Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning.

Authors:  Joseph Ventura; Tamara Welikson; Arielle Ered; Kenneth L Subotnik; Richard S E Keefe; Gerhard S Hellemann; Keith H Nuechterlein
Journal:  Early Interv Psychiatry       Date:  2019-06-10       Impact factor: 2.732

5.  A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

Authors:  Ryan Dammerman; Sonnie Kim; Mathews Adera; Alex Schwarz
Journal:  Psychopharmacol Bull       Date:  2017-09-15

6.  Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience.

Authors:  Philip D Harvey; Anzalee Khan; Richard S E Keefe
Journal:  Innov Clin Neurosci       Date:  2017-12-01

7.  Predictors of social functioning in patients with higher and lower levels of reduced emotional experience: Social cognition, social competence, and symptom severity.

Authors:  Philip D Harvey; Elizabeth Deckler; Fredrik Jarskog; David L Penn; Amy E Pinkham
Journal:  Schizophr Res       Date:  2018-11-13       Impact factor: 4.939

8.  Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder.

Authors:  Margaret M McClure; Fiona Graff; Joseph Triebwasser; Mercedes Perez-Rodriguez; Daniel R Rosell; Harold Koenigsberg; Erin A Hazlett; Larry J Siever; Philip D Harvey; Antonia S New
Journal:  Am J Psychiatry       Date:  2019-01-18       Impact factor: 18.112

9.  An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.

Authors:  Darrick T Balu; Yan Li; Shunsuke Takagi; Kendall Taylor Presti; Teniel S Ramikie; Jerri M Rook; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn; Vadim Y Bolshakov; Joseph T Coyle
Journal:  Neuropsychopharmacology       Date:  2016-01-07       Impact factor: 7.853

10.  Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia: A Network Analysis.

Authors:  Silvana Galderisi; Paola Rucci; Brian Kirkpatrick; Armida Mucci; Dino Gibertoni; Paola Rocca; Alessandro Rossi; Alessandro Bertolino; Gregory P Strauss; Eugenio Aguglia; Antonello Bellomo; Martino Belvederi Murri; Paola Bucci; Bernardo Carpiniello; Anna Comparelli; Alessandro Cuomo; Domenico De Berardis; Liliana Dell'Osso; Fabio Di Fabio; Barbara Gelao; Carlo Marchesi; Palmiero Monteleone; Cristiana Montemagni; Giulia Orsenigo; Francesca Pacitti; Rita Roncone; Paolo Santonastaso; Alberto Siracusano; Annarita Vignapiano; Antonio Vita; Patrizia Zeppegno; Mario Maj
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.